Kanaph Therapeutics

Kanaph Therapeutics (Ticker: 0082N0 KS) develops targeted experimental medicines, including treatments being studied for solid tumors such as lung and colorectal cancer. Its candidate KNP-101 targets FAP and uses interleukin-12; it is intended to address the immunosuppressive environment around tumors.

The scheduled listing date on Korea Exchange (KOSDAQ) was March 16, 2026. The proposed offering comprises 2,000,000 shares at an indicative price of KRW 20000 per share. The base offering would represent KRW 40.00 billion, approximately $30.08 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is $179.45 million.